Kalaris Therapeutics Inc
NASDAQ:KLRSBiotechnology
+$0.16 today
- Market cap
- $54.75M
- Beta
- 0.14
- P/E (TTM)
- -2.5
- EPS (TTM)
- -$1.86
Volume 0.07M
Average 0.08M
KLRS Weighted Avg Shares (Diluted)
Average shares outstanding including dilutive securities, used to calculate diluted EPS.
Kalaris Therapeutics IncNASDAQ: KLRS
Weighted Avg Shares (Diluted) · Q1 FY2026 · quarter ended Mar 2026
Weighted avg shares (diluted) growth accelerates
Q1 FY2026 weighted avg shares (diluted) of 23.72M shares rose 485.3% year over year, ahead of the +341.4% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it rose 3.6% from the prior quarter. Over 3 fiscal years it compounded at +66.1% a year.
Context
- Weighted avg shares (diluted) increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +485.3% holds above the trailing-twelve-month pace of +341.4%.
Sources:Income StatementText generated from reported figures; not investment advice.
Weighted Avg Shares (Diluted) history
Shares · from the income statement
- Latest · FY2025
- 15.27M USD
- Year-over-year change
- +204.8%
- 4-year CAGR
- +53.8%
| Period | Period end | Weighted Avg Shares (Diluted) | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 15.27M | +204.8% |
| FY2024 | 2024-12-31 | 5.01M | +10.7% |
| FY2023 | 2023-12-31 | 4.52M | +35.7% |
| FY2022 | 2022-12-31 | 3.33M | +22.1% |
| FY2021 | 2021-12-31 | 2.73M | — |
Weighted Avg Shares (Diluted) vs competitors
How KLRS compares with its peers on the latest reported figures
- KLRS's LTM Mar 2026 weighted avg shares (diluted) of 21.01M shares is the 7th highest of the 9 companies compared; the peer median is 62.26M shares.
- Its year-over-year change of +341.4% is the highest of 9, against a peer median of +3.2%.
- Over three fiscal years its annual growth of +66.1% compares with a peer median of +13.3%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Mar 2026 | 94.36M | +30.6% | +81.3% | |
| LTM Mar 2026 | 84.8M | +66.7% | +18.0% | |
| LTM Mar 2026 | 74.41M | +4.7% | +1.5% | |
| LTM Mar 2026 | 68.86M | +14.8% | +15.0% | |
| FY2025 | 55.66M | +0.8% | +0.4% | |
ARTVArtiva Biotherapeutics, Inc. | LTM Mar 2026 | 24.5M | +1.8% | +11.6% |
KLRSKalaris Therapeutics Inc | LTM Mar 2026 | 21.01M | +341.4% | +66.1% |
IMAImageneBio Inc | LTM Mar 2026 | 19.79M | -59.0% | -48.8% |
| LTM Mar 2026 | 6.42M | -22.0% | +18.8% | |
| Peer median (excluding KLRS) | 62.26M | +3.2% | +13.3% | |
Competitors are the stored peer set for KLRS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 1.12M | 0 | 0 | 0 | 13K |
| Gross Profit | (1.12M) | 0 | 0 | 0 | (13K) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 119.62M | 11.76M | 11.71M | 12.34M | 30.75M |
| Selling, General & Admin | 49.08M | 2.24M | 1.76M | 42.92M | 15.39M |
| Operating Expenses | 168.7M | 14.01M | 13.46M | 55.26M | 46.14M |
| Depreciation & Amortization | 1.12M | 0 | 0 | 0 | 13K |
| EBITDA | (169.84M) | (15.25M) | (14.01M) | (58.77M) | (41.98M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (169.82M) | (14.01M) | (13.46M) | (55.26M) | (46.15M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 1.32M | 0 | 0 | 5.49M | 0 |
| Interest Expense | 0 | 235K | 687K | 0 | 1.44M |
| Other Income / Expenses | (1.14M) | (1.48M) | (1.24M) | (3.51M) | 2.71M |
| Income Before Tax | (170.96M) | (15.49M) | (14.7M) | (58.77M) | (43.44M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 1.01M | 0 | 0 | 0 | 0 |
| Net Income | (171.96M) | (15.49M) | (14.7M) | (58.77M) | (43.44M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (63.00) | (50.62) | (42.09) | (11.73) | (2.85) |
| EPS (Diluted) | (63.00) | (50.62) | (42.09) | (11.73) | (2.85) |
| Weighted Avg Shares | 2.73M | 3.33M | 4.52M | 5.01M | 15.27M |
| Weighted Avg Shares (Diluted) | 2.73M | 3.33M | 4.52M | 5.01M | 15.27M |
Kalaris Therapeutics Inc
NASDAQ:KLRS
Intrinsic Alpha fair value
Locked
Current Price
$2.30
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.